Find the artificial intelligence based software for pathology that you are looking for. All products listed are available for the European market (CE-IVD marked).
The data presented in the pathology domain is under a publication embargo until May 2026 and should not be used for publication purposes until the embargo period has ended.
105 of 105 products
105/105
products
|
Sort by:
Subspeciality: Breast
Modality: Histopathology
Source: Public
No key features available
The DiaKwant™ HER2 algorithms assist pathologists in evaluating hormonal and proliferative biomarkers.
Subspeciality: Breast
Modality: Histopathology
Source: Public
No key features available
The DiaKwant™ ER/PR algorithm assists pathologists in evaluating hormonal and proliferative biomarkers.
Subspeciality: Breast
Modality: Histopathology
Source: Public
No key features available
The DiaKwant™ Ki-67 algorithms assist pathologists in evaluating hormonal and proliferative biomarkers.
Subspeciality: Multiple
Modality: Histopathology
Source: Public
No key features available
DiaKwant™ PD-L1 automatically detects tumor regions and the surrounding microenvironment on IHC slides. DiaKwant™ algorithm identifies tumor and immune cells, quantifies PD-L1–positive cells, and computes CPS and TPS at the whole-slide level.
Subspeciality: Breast
Modality: Histopathology
Source: Public
No key features available
"DiaKwant™ Mitosis automatically detects invasive tumor regions on H&E slides and identifies mitotic figures.
It highlights candidate mitoses, classifies them, and generates interpretable heatmaps and hotspot-based mitotic scores.
"(https://www.diadeep.com/diakwant)
Subspeciality: Gastrointestinal pathology
Modality: Histopathology
Source: Public
Biomarker prediction
MSIntuit CRC is an AI digital pathology diagnostic solution that pre-screens for a biomarker in colorectal cancer tumors known as microsatellite instability (MSI) – a defect in a cell’s ability to correct mistakes that occur when DNA is copied. This diagnostic rules out microsatellite stable (MSS) phenotypes, allowing pathologists to concentrate their resources on confirming those patients who exhibit MSI.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Public
Risk stratification
RlapsRisk BC is an AI prognostic solution that predicts whether a breast cancer patient (ER+/HER2-) will go on to relapse after treatment, informing oncologists which high-risk patients may benefit from targeted therapies and which low-risk patients could potentially avoid chemotherapy.
Subspeciality: Uropathology
Modality: Histopathology
Source: Public
No key features available
The ArteraAI Prostate Test can be used for patients across all NCCN risk groups, with 10-year risk of distant metastasis (DM) and prostate cancer-specific mortality (PCSM) reported and can be used to assess how aggressive the cancer is.
Subspeciality: Gynecologic cytopathology
Modality: Cytopathology
Source: Public
Cervical cancer cells, Glandular component, Identifying pre-cancerous lesions, Infectious organisms
Genius Cervical AI is a new artificial intelligence (AI) for cervical cancer screening that assists in identifying pre-cancerous lesions and cervical cancer cells, infectious organisms, and glandular component from patient samples imaged on the Genius Digital Imager.
Subspeciality: Gynecologic cytopathology
Modality: Cytopathology
Source: Vendor
Abnormal Gallery & Prioritization, AI-Powered Image Analysis, Automated Background Processing, Remote Access & Virtual Microscopy Tool, Web-Based
Datexim CytoProcessor is a digital pathology platform designed to enhance cervical cytology diagnosis by combining artificial intelligence, clinical expertise, and workflow integration.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Vendor
Calcification detection, DCIS detection, IC detection, lymph node metastasis detection, Mitosis count
CLEO BREAST is a software for use with digitized H&E stained breast biopsy & excision tissues. CLEO BREAST employs AI-based algorithms to assist pathologists in their diagnostic journey, integrating AI-enhanced tools to detect the presence of critical biomarkers, such as Invasive Carcinoma, Metastases, Mitoses, Calcifications and Emboli. By incorporating these models, CLEO BREAST not only streamlines the diagnostic process but also heightens its precision. This approach aids pathologists in elevating diagnostic accuracy, curtailing turnaround times, and optimizing lab efficiency. The pathologist has to review the results of CLEO BREAST and is responsible for the final diagnosis.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Vendor
Cancer detection, Cell classification, Proliferation Score, Tissue segmentation
Software for automated analysis of digital histopathology images of invasive mamma carcinoma tissue samples. It supports the analysis of digital images from scanned, Ki-67 stained samples of invasive ductal and lobular carcinoma. The software detects and classifies IHC-stained tumor cells in whole slide image, identifies one or several tumor regions according to the hotspot method, and provides a proliferation score. Tumor cells are classified as not-stained (tumor negative) or stained (tumor positive). Pathologist has to review the results and is responsible for the final diagnosis.
